These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 34214632)
1. Quantitative evaluation of PpSP15-LmSTI1 fusion gene expression following transfection with an alphavirus-derived self-amplifying mRNA and conventional DNA vaccine platforms. Savar NS; Vallet T; Azizi M; Arashkia A; Lundstrom K; Vignuzzi M; Niknam HM Mol Cell Probes; 2021 Oct; 59():101749. PubMed ID: 34214632 [TBL] [Abstract][Full Text] [Related]
2. An alphavirus-derived self-amplifying mRNA encoding PpSP15-LmSTI1 fusion protein for the design of a vaccine against leishmaniasis. Savar NS; Shengjuler D; Doroudian F; Vallet T; Mac Kain A; Arashkia A; Khamesipour A; Lundstrom K; Vignuzzi M; Niknam HM Parasitol Int; 2022 Aug; 89():102577. PubMed ID: 35301120 [TBL] [Abstract][Full Text] [Related]
3. Packaging, Purification, and Titration of Replication-Deficient Semliki Forest Virus-Derived Particles as a Self-Amplifying mRNA Vaccine Vector. Savar NS; Vallet T; Arashkia A; Lundstrom K; Vignuzzi M; Mahmoudzadeh Niknam H Iran Biomed J; 2022 Jul; 26(4):269-78. PubMed ID: 35468712 [TBL] [Abstract][Full Text] [Related]
4. Construction of a Novel DNA Vaccine Candidate encoding LmSTI1-PpSP42 Fusion Protein from Miandoabi T; Bahrami F; Moein Vaziri V; Ajdary S Rep Biochem Mol Biol; 2018 Oct; 7(1):67-75. PubMed ID: 30324120 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969 [TBL] [Abstract][Full Text] [Related]
6. Alphavirus DNA and particle replicons for vaccines and gene therapy. Polo JM; Gardner JP; Ji Y; Belli BA; Driver DA; Sherrill S; Perri S; Liu MA; Dubensky TW Dev Biol (Basel); 2000; 104():181-5. PubMed ID: 11713818 [TBL] [Abstract][Full Text] [Related]
7. A new generation of vaccines based on alphavirus self-amplifying RNA. Ballesteros-Briones MC; Silva-Pilipich N; Herrador-Cañete G; Vanrell L; Smerdou C Curr Opin Virol; 2020 Oct; 44():145-153. PubMed ID: 32898764 [TBL] [Abstract][Full Text] [Related]
8. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens. Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118 [TBL] [Abstract][Full Text] [Related]
10. Expression of H5N1 influenza virus hemagglutinin protein fused with protein transduction domain in an alphavirus replicon system. Yang SG; Wo JE; Li MW; Mi FF; Yu CB; Lv GL; Cao HC; Lu HF; Wang BH; Zhu H; Li LJ J Virol Methods; 2010 Jan; 163(1):31-9. PubMed ID: 19646478 [TBL] [Abstract][Full Text] [Related]
11. A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice. Liu S; Gong Q; Wang C; Liu H; Wang Y; Guo S; Wang W; Liu J; Shao M; Chi L; Zhao K; Wang Z; Shi Y; Huang Y; Guli A; Zhang C; Kong X Immunol Lett; 2008 May; 117(2):136-45. PubMed ID: 18339431 [TBL] [Abstract][Full Text] [Related]